94 results
8-K
EX-99.1
SCYX
Scynexis Inc
5 Jan 24
A dynamic force in the fight against infectious disease January 2024
9:53am
) by bringing a ground-breaking class of drugs with the strength, safety and versatility to defeat even the most insidious fungal diseases Increase
424B5
SCYX
Scynexis Inc
28 Nov 23
Prospectus supplement for primary offering
4:05pm
. To date, we have characterized the antifungal activity, pharmacokinetics, and safety profile of the oral and IV formulations of ibrexafungerp in multiple
424B5
SCYX
Scynexis Inc
28 Nov 23
Prospectus supplement for primary offering
4:05pm
.) and Europe. To date, we have characterized the antifungal activity, pharmacokinetics, and safety profile of the oral and IV formulations of ibrexafungerp
8-K
ajtc7q6h0mls58
30 Mar 23
Entry into a Material Definitive Agreement
7:08am
8-K
EX-99.1
w55ngq
9 Nov 22
SCYNEXIS Reports Third Quarter 2022 Financial Results
7:16am
8-K
EX-99.1
kid43c3
15 Aug 22
SCYNEXIS Reports Second Quarter 2022 Financial Results
9:41am